

Advances in the Delayed-Onset of Type 1 Diabetes: Strategies to Improve Awareness and Care for the Practicing Clinician

Guidelines and Practice Parameters

Resource	Address
American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of care in diabetes—2024. <i>Diabetes Care</i> . 2024;47(suppl 1):S20-S42.	https://diabetesjournals.org/care/article/47/Supplement_1/S20/153954
American Diabetes Association Professional Practice Committee. 3. Prevention or delay of diabetes and associated comorbidities: Standards of care in diabetes—2024. <i>Diabetes Care</i> . 2024;47(suppl 1):S43-S51.	https://diabetesjournals.org/care/article/47/Supplement_1/S43/153945
Besser REJ, Bell KJ, Couper JJ, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. <i>Pediatr Diabetes</i> . 2022;23:1175-1187.	https://cdn.ymaws.com/www.ispad.org/resource/resmgr/consensus_guidelines_2018_/guidelines2022/ch.2_pediatric_diabetes_-_2.pdf
Mehta S, Ryabets-Lienhard A, Patel N, et al. Pediatric Endocrine Society statement on considerations for the use of teplizumab in clinical practice. <i>Horm Res Paediatr</i> . 2024;Apr 30:1-12.	https://pubmed.ncbi.nlm.nih.gov/38663372/
Philip M, Achenbach P, Addala A, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. <i>Diabetes Care</i> . 2024;Jun 24:dci240042.	https://pubmed.ncbi.nlm.nih.gov/38912694/

References/Reading List

Resource	Address
Atkinson MA, Mirmira RG. The pathogenic "symphony" in type 1 diabetes: A disorder of the immune system, β cells, and exocrine pancreas. <i>Cell Metab</i> . 2023;35:1500-1518.	https://pubmed.ncbi.nlm.nih.gov/37478842/
Bogun MM, Bundy BN, Goland RS, Greenbaum CJ. C-peptide levels in subjects followed longitudinally before and after type 1 diabetes diagnosis in TrialNet. <i>Diabetes Care</i> . 2020;43:1836-1842.	https://pubmed.ncbi.nlm.nih.gov/32457058/
Fyvie MJ, Gillespie KM. The importance of biomarker development for monitoring type 1 diabetes progression rate and therapeutic responsiveness. <i>Front Immunol</i> . 2023;14:1158278.	https://pubmed.ncbi.nlm.nih.gov/37256143/
Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. <i>N Engl J Med</i> . 2019;381:603-613.	https://pubmed.ncbi.nlm.nih.gov/31180194/
Herold KC, Gitelman SE, Gottlieb PA, et al. Teplizumab: A disease-modifying therapy for type 1 diabetes that preserves β -Cell function. <i>Diabetes Care</i> . 2023;46:1848-1856.	https://pubmed.ncbi.nlm.nih.gov/37607392/

Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> . 2021;44:2589-2625.	https://pubmed.ncbi.nlm.nih.gov/34593612/
Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. <i>Diabetes Care</i> . 2015;38:1964-1974.	https://pubmed.ncbi.nlm.nih.gov/26404926/
Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. <i>Nat Rev Dis Primers</i> . 2017;3:17016.	https://pubmed.ncbi.nlm.nih.gov/28358037/
Leslie RD, Evans-Molina C, Freund-Brown J, et al. Adult-onset type 1 diabetes: Current understanding and challenges. <i>Diabetes Care</i> . 2021;44:2449-2456.	https://pubmed.ncbi.nlm.nih.gov/34670785/
Linsley PS, Greenbaum CJ, Nepom GT. Uncovering pathways to personalized therapies in type 1 diabetes. <i>Diabetes</i> . 2021;70:831-841.	https://pubmed.ncbi.nlm.nih.gov/33741606/
O'Donnell HK, Rasmussen CG, Dong F, et al. Anxiety and risk perception in parents of children identified by population screening as high risk for type 1 diabetes. <i>Diabetes Care</i> . 2023;46:2155-2161.	https://pubmed.ncbi.nlm.nih.gov/37673098/
Ospelt E, Hardison H, Rioles N, et al. Understanding providers' readiness and attitudes toward autoantibody screening: A mixed-methods study. <i>Clin Diabetes</i> . 2024;42:17-26.	https://pubmed.ncbi.nlm.nih.gov/38230325/
Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and β -Cell function in newly diagnosed type 1 diabetes. <i>N Engl J Med</i> . 2023;389:2151-2161.	https://pubmed.ncbi.nlm.nih.gov/37861217/
Simmons KM, Sims EK. Screening and prevention of type 1 diabetes: Where are we? <i>J Clin Endocrinol Metab</i> . 2023;108:3067-3079.	https://pubmed.ncbi.nlm.nih.gov/37290044/
Simmons KMW, Frohnert BI, O'Donnell HK, et al. Historical insights and current perspectives on the diagnosis and management of presymptomatic type 1 diabetes. <i>Diabetes Technol Ther</i> . 2023;25:790-799.	https://pubmed.ncbi.nlm.nih.gov/37695674/
Sims EK, Besser REJ, Dayan C, et al. Screening for type 1 diabetes in the general population: A status report and perspective. <i>Diabetes</i> . 2022;71:610-623.	https://pubmed.ncbi.nlm.nih.gov/35316839/
Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. <i>Sci Transl Med</i> . 2021;13:eabc8980.	https://pubmed.ncbi.nlm.nih.gov/33658358/
Smigoc Schweiger D. Recent advances in immune-based therapies for type 1 diabetes. <i>Horm Res Paediatr</i> . 2023;96:631-645.	https://pubmed.ncbi.nlm.nih.gov/35533645/
VanBuecken D, Lord S, Greenbaum CJ. Changing the course of disease in type 1 diabetes. In: Feingold KR, Anawalt B, Blackman MR, eds. <i>Endotext</i> [Internet]. MDText.com; January 6, 2022.	https://www.ncbi.nlm.nih.gov/books/NBK326738/

Resources and Societies

Resource	Address
American Diabetes Association®. Summary of the American Diabetes Association® Type 1 Diabetes Screening & Awareness Roundtable. December 15, 2023.	https://diabetes.org/sites/default/files/2024-04/ADA-T1D-Screening-and-Awareness-Roundtable-Report.pdf
ASK (Autoimmunity Screening for Kids). T1D screening program.	https://www.askhealth.org/
Breakthrough T1D. Enrolling in Clinical Trials.	https://www.breakthrought1d.org/clinical-trials/
Breakthrough T1D. Breakthrough T1D Early detection.	https://www.breakthrought1d.org/early-detection/
CASCADE Research Study. Type 1 diabetes and celiac disease screening for children in the state of Washington.	https://cascadekids.org/
Sanford Research. PLEDGE Pediatric Screening Program.	https://research.sanfordhealth.org/fields-of-research/diabetes/pledge
Type 1 Diabetes TrialNet. For Healthcare Providers: TrialNet Recommendations for Clinicians.	https://www.trialnet.org/healthcare-providers
Type 1 Diabetes TrialNet. Resources for T1D screening & national T1D screening program.	https://www.trialnet.org/
University of Colorado – Barbara Davis Center for Diabetes. Ask the experts for early T1D answers and guidance.	https://www.asktheexperts.org/

All URLs accessed June 24, 2024